Andrew Burke

Dr. Andrew Burke

orcid

Research Focus & Metrics

Academic Career Length

12Years (2015-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
22 September 2023 in Chest
Verified
Journal Article
Closed access
LLLawrence Yanxi Lu
Lawrence Yanxi Lu
HLHui Min Lee
Hui Min Lee
ABAndrew Burke
Andrew Burke
GBGianluigi Li Bassi
Gianluigi Li Bassi
ATAntoni Torres
Antoni Torres
JFJonathon P. Fanning
Jonathon P. Fanning

17 June 2024 in Pharmaceutics
Verified
Journal Article
Open access
PDF file
Ricky Hao ChenRicky Hao Chen
Ricky Hao Chen
ABAndrew Burke
Andrew Burke
JCJin-Gun Cho
Jin-Gun Cho
JAJan-Willem C Alffenaar
Jan-Willem C Alffenaar
LFLina Davies Forsman
Lina Davies Forsman
Multidrug-resistant tuberculosis (MDR-TB) is a global health concern. Standard treatment involves the use of linezolid, a repurposed oxazolidinone. It is associated with severe adverse effects, including myelosuppression and mitochondrial toxicity. As such, it is imperative to identify novel alternatives that are better tolerated but equally or more effective. Therefore, this review aims to identify and explore the novel alternative oxazolidinones to potentially replace linezolid in the management of TB. The keywords tuberculosis and oxazolidinones were searched in PubMed to identify eligible compounds. The individual drug compounds were then searched with the term tuberculosis to identify the relevant in vitro, in vivo and clinical studies. The search identified sutezolid, tedizolid, delpazolid, eperezolid, radezolid, contezolid, posizolid and TBI-223, in addition to linezolid. An additional search resulted in 32 preclinical and 21 clinical studies. All novel oxazolidinones except posizolid and eperezolid resulted in positive preclinical outcomes. Sutezolid and delpazolid completed early phase 2 clinical studies with better safety and equal or superior efficacy. Linezolid is expected to continue as the mainstay therapy, with renewed interest in drug monitoring. Sutezolid, tedizolid, delpazolid and TBI-223 displayed promising preliminary results. Further clinical studies would be required to assess the safety profiles and optimize the dosing regimens.

27 June 2022 in Trials
Verified
Journal Article
Open access
PDF file
DFDeirdre B Fitzgerald
Deirdre B Fitzgerald
CSCalvin Sidhu
Calvin Sidhu
CBCharley Budgeon
Charley Budgeon
ATAi Ling Tan
Ai Ling Tan
CRCatherine A. Read
Catherine A. Read
YLY C Gary Lee
Y C Gary Lee
Introduction: Malignant pleural effusions (MPEs) are common. MPE causes significant breathlessness and impairs quality of life. Indwelling pleural catheters (IPC) allow ambulatory drainage and reduce hospital days and re-intervention rates when compared to standard talc slurry pleurodesis. Daily drainage accelerates pleurodesis, and talc instillation via the IPC has been proven feasible and safe. Surgical pleurodesis via video-assisted thoracoscopic surgery (VATS) is considered a one-off intervention for MPE and is often recommended to patients who are fit for surgery. The AMPLE-3 trial is the first randomised trial to compare IPC (±talc pleurodesis) and VATS pleurodesis in those who are fit for surgery. Methods and analysis: A multi-centre, open-labelled randomised trial of patients with symptomatic MPE, expected survival of ≥ 6 months and good performance status randomised 1:1 to either IPC or VATS pleurodesis. Participant randomisation will be minimised for (i) cancer type (mesothelioma vs non-mesothelioma); (ii) previous pleurodesis (vs not); and (iii) trapped lung, if known (vs not). Primary outcome is the need for further ipsilateral pleural interventions over 12 months or until death, if sooner. Secondary outcomes include days in hospital, quality of life (QoL) measures, physical activity levels, safety profile, health economics, adverse events, and survival. The trial will recruit 158 participants who will be followed up for 12 months. Ethics and dissemination: Sir Charles Gairdner and Osborne Park Health Care Group (HREC) has approved the study (reference: RGS356). Results will be published in peer-reviewed journals and presented at scientific meetings. Discussion: Both IPC and VATS are commonly used procedures for MPE. The AMPLE-3 trial will provide data to help define the merits and shortcomings of these procedures and inform future clinical care algorithms. Trial registration: Australia New Zealand Clinical Trial Registry ACTRN12618001013257. Registered on 18 June 2018. Protocol version: Version 3.00/4.02.19

27 March 2023 in Transplant Infectious Disease
Verified
Journal Article
Closed access
CDChandima Divithotewala
Chandima Divithotewala
ESEmma L. Sweeney
Emma L. Sweeney
ABAndrew Burke
Andrew Burke
BGBianca Graves
Bianca Graves
ASAdam Stewart
Adam Stewart
DCDaniel C. Chambers
Daniel C. Chambers

19 October 2015 in Medical Journal of Australia
Verified
Journal Article
Closed access
ABAndrew Burke
Andrew Burke
SGStephen R Graves
Stephen R Graves
NANicholas M Anstey
Nicholas M Anstey
Always obtain a complete travel and exposure history when assessing febrile travellers, and not just their most recent travel

14 August 2023 in Clinics in Chest Medicine
Verified
Journal Article
Closed access
ASAlice Sawka
Alice Sawka
ABAndrew Burke
Andrew Burke